These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 15352995)
1. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia. Cacciola RR; Francesco ED; Giustolisi R; Cacciola E Br J Haematol; 2004 Sep; 126(6):885-6. PubMed ID: 15352995 [No Abstract] [Full Text] [Related]
2. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide. Cacciola RR; Cipolla A; Di Francesco E; Giustolisi R; Cacciola E Am J Hematol; 2005 Sep; 80(1):81-3. PubMed ID: 16138352 [TBL] [Abstract][Full Text] [Related]
3. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866 [No Abstract] [Full Text] [Related]
4. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide. Griesshammer M Expert Rev Hematol; 2009 Jun; 2(3):227-36. PubMed ID: 21082965 [TBL] [Abstract][Full Text] [Related]
5. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide. Andersson BS Hematology; 2002 Jun; 7(3):173-7. PubMed ID: 12243981 [No Abstract] [Full Text] [Related]
9. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ; Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452 [TBL] [Abstract][Full Text] [Related]
10. Anagrelide: what was new in 2004 and 2005? Petrides PE Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615 [TBL] [Abstract][Full Text] [Related]
11. Long-term use of anagrelide in the treatment of children with essential thrombocythemia. Lackner H; Urban C; Benesch M; Moser A; Sovinz P; Schwinger W; Dornbusch HJ Eur J Haematol; 2006 Oct; 77(4):358-9. PubMed ID: 16856926 [No Abstract] [Full Text] [Related]
12. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting. Ito T; Hashimoto Y; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982 [TBL] [Abstract][Full Text] [Related]
13. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Cascavilla N; De Stefano V; Pane F; Pancrazzi A; Iurlo A; Gobbi M; Palandri F; Specchia G; Liberati AM; D'Adda M; Gaidano G; Fjerza R; Achenbach H; Smith J; Wilde P; Vannucchi AM Drug Des Devel Ther; 2015; 9():2687-94. PubMed ID: 26028965 [TBL] [Abstract][Full Text] [Related]
14. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR]. Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099 [TBL] [Abstract][Full Text] [Related]
15. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. Wong RS; Lam LW; Cheng G Ann Hematol; 2008 Aug; 87(8):683-4. PubMed ID: 18299832 [No Abstract] [Full Text] [Related]
16. [Anagrelide for treatment of patients with essential thrombocythaemia]. Boban A; Sertić D; Radman I; Zupancić-Salek S; Zadro R; Labar B Lijec Vjesn; 2008; 130(5-6):141-5. PubMed ID: 18792562 [TBL] [Abstract][Full Text] [Related]
17. [Hematologic Malignancies/Pediatric Malignancies. II. Treatment of Essential Thrombocythemia--The Role of Anagrelide]. Kitanaka A; Shimoda K Gan To Kagaku Ryoho; 2016 May; 43(5):535-8. PubMed ID: 27344681 [No Abstract] [Full Text] [Related]
18. Treatment of essential thrombocythemia in childhood. Scherer S; Ferrari R; Rister M Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533 [TBL] [Abstract][Full Text] [Related]
19. [Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide]. Laguna MS; Kornblihtt LI; Marta RF; Molinas FC Medicina (B Aires); 2000; 60(4):448-52. PubMed ID: 11188949 [TBL] [Abstract][Full Text] [Related]
20. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience]. Kornblihtt LI; Vassallu PS; Heller P; Molinas FC Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]